Navigating PD-L1 testing in immuno-oncology: analytical robustness, clinical validation, and the role of the VENTANA SP263 assay
{{output}}
Introduction: PD-L1 expression today represents a crucial biomarker in the selection of patients eligible for immune checkpoint inhibitor therapies (PD-1/PD-L1), particularly in tumors such as NSCLC, urothelial carcinoma, and TNB... ...
